About The Study: Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase, a modified human tissue plasminogen activator, administered 4.5 to 24 hours after onset resulted in a greater likelihood of an excellent functional outcome at 90 days than standard care but had an increased risk of symptomatic intracranial hemorrhage.
Corresponding Author: To contact the corresponding author, Junwei Hao, MD, PhD, email haojunwei@vip.163.com .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.0210)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the International Stroke Conference 2026 of the American Heart Association.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.0210?guestAccessKey=ee846c72-94a4-471b-a5f0-0d752321bdeb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020526
JAMA